For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| PHMB 0.08% Plus Placebo | polihexanide (PHMB) 0.08% and placebo were administered in the affected eye until clinical resolution for a maximum of 12 months | 0 | None | 0 | 69 | 31 | 69 | View |
| PHMB 0.02% Plus Propamidine 0.1% | polihexanide (PHMB) 0.02% and propamidine 0.1% were administered in the affected eye until clinical resolution for a maximum of 12 months | 0 | None | 0 | 65 | 29 | 65 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| eye pain | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| ocular hyperemia | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| lacrimation increased | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| conjunctival hyperemia | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| eye irritation | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| photophobia | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| eye inflammation | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| corneal epithelium defect | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| eye pruritus | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| eye discharge | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| eye swelling | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| keratitis | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| ocular discomfort | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |
| corneal infiltrates | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (Unspecified) | View |